Breaking Now: Nutriband Inc. (NASDAQ: NTRB) Moves Approx 38% on Early Announcement

*Sponsored by Nutriband Inc. Market Crux Exclusive! Hot Off the Press: Nutriband Inc. (NASDAQ: NTRB) Just Made Headlines—Now Topping Our Watchlist This Thursday Morning. Nutriband Inc. (NASDAQ: NTRB) Comes Backed By Several  Potential Catalysts Including: With fewer than 5.1M shares in the float, (NTRB) has shown the potential for significant swings, including an approximate 202% move in one week. (NTRB) is trending above key moving averages, including the 50-day at $5.39, 100-day at $5.66, and the 200-day at $5.49, signaling continued momentum. Insider ownership stands at over 54%, and Noble Capital’s Robert LeBoyer recently set a $13 target, suggesting over 90% upside potential. Consider adding Nutriband Inc. (NASDAQ: NTRB) to your radar today. February 13, 2025 Dear Reader, What a way to start the day. (NTRB) just reached $9.88 in the pre-market, moving approximately 38% from yesterday’s $7.12 close.  Nutriband Inc. (NASDAQ: NTRB) has just formalized an exclusive partnership with Kindeva Dr-ug Delivery to co-develop Aversa™ Fent-a-nyl, an abuse-deterrent fent-a-nyl patch that could reshape pain management. The agreement outlines a long-term commitment with shared development costs and milestone-driven incentives.  With Kindeva’s expertise in transdermal drug delivery and Nutriband Inc. (NASDAQ: NTRB)’s proprietary Aversa™ technology, this collaboration could accelerate progress toward FDA submission and commercialization.   Given the product’s potential to generate $80M–$200M in U.S. sales annually, this partnership marks a significant milestone in Nutriband Inc. (NASDAQ: NTRB)’s path forward. This under-the-radar pharma company has already turned heads twice, making approximate moves of 32% in under 24 hours and approx. 126% in less than 48 hours.  With this latest development, it’s back on our radar in a big way. Now, it’s going for the hat trick—and if you don’t know what that means, let’s clear it up. A hat trick is when the same player scores three times in a row.  And if this profile pulls it off again, anyone still sitting on the sidelines might start kicking themselves. Let’s not waste time. See why Nutriband Inc. (NASDAQ: NTRB) is topping our watchlist this morning. Let’s call it like it is—few biotech companies are pushing boundaries quite like Nutriband Inc. (NASDAQ: NTRB). While others stick to tired formulas and incremental changes, Nutriband Inc. (NASDAQ: NTRB) is establishing itself as a leader in the development of advanced transdermal technologies, addressing some of the most critical challenges in healthcare today. With a low float of less than 5.1M shares listed, we’re keeping a close eye on Nutriband Inc. (NASDAQ: NTRB) because this scarcity could lead to the potential for significant swings if demand begins to change.  In fact, Nutriband Inc. (NASDAQ: NTRB) recently moved approximately 202% in one week, from $3.90 on January 16th to $11.78 on January 23, 2025. Analyst Target Suggests Over 90% Upside Potential Recently trending above several key moving averages, Nutriband Inc. (NASDAQ: NTRB) is showing strong technical momentum.  With its 50-day at $5.39, 100-day at $5.66, and 200-day at $5.49, (NTRB) is currently trending above all long-term indicators tracked by Barchart—a bullish signal that could suggest further upside potential.  Additionally, its year-to-date moving average of $6.29 reinforces the notion that (NTRB) has been maintaining strength despite broader market fluctuations. Backing this momentum, insider ownership stands at over 54% as of (yesterday) 2/12/2025—an exceptionally strong vote of confidence from those who know the company best.  With more than half of all shares held by insiders, leadership is signaling long-term commitment and belief in future growth. This combination of technical strength and a market cap under $77M, could position (NTRB) as a high-growth candidate compared to larger players in the same space. Less than a month ago, Noble Capital’s Robert LeBoyer initiated coverage on (NTRB) with a Bullish Rating and a $13 target, which suggests over 90% upside potential from yesterday’s $6.90 open. Nutriband Inc. (NASDAQ: NTRB) Advances Phase 1 Trial,  Eyes FDA Filing in 2025 At the heart of this optimism is Nutriband Inc. (NASDAQ: NTRB)’s Phase 1 clinical trial, which is expected to showcase the effectiveness of its abuse-deterrent technology, setting up for an NDA filing by late 2025 and potential FDA approval in 2026. With a clear roadmap and strong momentum, Nutriband Inc. (NASDAQ: NTRB) continues to gain attention.  While many companies struggled to stay relevant, (NTRB) stayed on course, reinforcing its strategy and delivering results. Nutriband Inc. (NASDAQ: NTRB) received a Notice of Allowance from the USPTO for its Aversa™ abuse-deterrent transdermal technology.  This expected patent issuance further strengthens its intellectual property portfolio and positions it as a key player in abuse-deterrent pharmaceuticals. Aversa™ Fent-a-nyl could be the first and only abuse-deterrent pain patch on the market, addressing a critical need in pain management.  Expanding Global Reach & Strengthening Market Position With patents secured in 46 countries—including the U.S., Europe, China, and Japan—Nutriband Inc. (NASDAQ: NTRB) is solidifying its global presence.  A recent U.S. trademark allowance further reinforces its leadership in transdermal abuse-deterrent technology.  If Aversa™ Fent-a-nyl reaches commercialization, U.S. sales projections range from $80M to $200M annually. Fiscal Strength & Growth Momentum Nutriband Inc. (NASDAQ: NTRB) continues to demonstrate strong financial performance, driven by its subsidiary Pocono Pharma: Q3 revenue up 51% year-over-year. $8.4M in fresh capital from a private placement strengthened fiscal reserves. This foundation supports the company’s efforts to bring Aversa™ Fent-a-nyl to market. Regulatory Progress & Market Expansion With an NDA submission planned for late 2025, Nutriband Inc. (NASDAQ: NTRB) is preparing for an expedited FDA review.  Meanwhile, strategic manufacturing partnerships and international licensing agreements are setting the stage for scalability beyond the U.S. market. A Pipeline with Potential—(NTRB) Targets Key Markets & Innovation Aversa™ Fent-a-nyl is just the beginning.  Nutriband Inc. (NASDAQ: NTRB) is also advancing AVERSA™ Buprenorphine and exploring additional transdermal applications, with Buprenorphine alone estimated to reach $130M annually. Nutriband Inc. (NASDAQ: NTRB) is expanding beyond pharmaceuticals with its consumer health and retail partnerships: Collaborations with Target, Walmart, Walgreens, and CVS. Exclusive supplier agreement with Fit For Life Group (Adidas, Reebok, New Balance). Launch of a Mosquito Repellent Patch in Costa Rica, tapping into the Central and South American markets. Strengthening the Brand with a Global Champion As Nutriband Inc. (NASDAQ: NTRB) continues to expand beyond pharmaceuticals, it has brought in elite athletic expertise to enhance its consumer product lineup. World and European Wrestling Gold Medalist and Olympic Silver Medalist Anastasia Nichita has joined Nutriband Inc. (NASDAQ: NTRB)’s Product Advisory Board, focusing on brand expansion and global promotion of its over-the-counter sports and consumer products. CEO Gareth Sheridan highlighted Nichita’s addition as a strategic move to amplify Nutriband’s market presence, leveraging her experience and international influence in the athletic world. Through its subsidiary Pocono Pharma, Nutriband produces various consumer products, including AI Tape—a kinesiology tape infused with soothing and therapeutic ingredients. With this high-profile appointment, Nutriband is reinforcing its commitment to innovation and brand expansion in the sports and wellness market. Why It Matters The opi-oid crisis remains one of the most pressing public health challenges. Nutriband Inc. (NASDAQ: NTRB) is not just talking about solutions—it’s delivering them. AVERSA™ technology is designed to prevent misuse, accidental exposure, and abuse of high-risk transdermal drugs. CEO Gareth Sheridan summed it up: Nutriband Inc. (NASDAQ: NTRB) is on the brink of a transformative period. See Nutriband Inc. (NASDAQ: NTRB)’s corporate presentation here. 7 Reasons Why Nutriband Inc. (NASDAQ: NTRB) is Topping Our Watchlist This Morning… 1. Limited Float: With under 5.1M shares in the float, (NTRB) has shown the potential for major swings, including an approximate 202% move in just one week. 2. Strong Technicals:  (NTRB) is currently near or above key moving averages, including the 50-day at $5.39, 100-day at $5.66, and 200-day at $5.49, while maintaining a year-to-date average of $6.29—potentially signaling further momentum. 3. Analyst Coverage: More than 54% of shares are insider-held, and Noble Capital’s Robert LeBoyer recently assigned a $13 target, which suggests over 90% potential upside from yesterday’s range. 4. Patent Advancement: The USPTO has issued a Notice of Allowance for (NTRB)’s Aversa™ abuse-deterrent technology, further reinforcing its intellectual property and positioning it as a leader in abuse-deterrent pharmaceuticals. 5. Market Expansion: With a planned NDA submission in late 2025, Aversa™ Fent-a-nyl could become the first and only abuse-deterrent transdermal patch, with estimated U.S. sales potential of $80M–$200M annually. 6. Fiscal Growth: A 51% year-over-year revenue increase and an additional $8.4M from a private placement have strengthened (NTRB)’s fiscal foundation, supporting continued product development and expansion. 7. International Footprint & Retail Growth: With patents secured in 46 countries, including the U.S., Europe, China, and Japan, (NTRB) continues expanding its global presence while also working with major retailers like Target, Walmart, Walgreens, and CVS in the consumer health sector. Consider Adding Nutriband Inc. (NASDAQ: NTRB) to Your  Radar This Morning… With a low float, strong technical positioning, and a bullish analyst target, Nutriband Inc. (NASDAQ: NTRB) isn’t just holding our attention—it’s demanding it.  A fresh patent allowance only strengthens its hold on the abuse-deterrent pharmaceutical space, while the push toward an NDA submission in 2025 could open doors to a first-of-its-kind market breakthrough.  Add in fiscal growth, an expanding global footprint, and partnerships with major retailers, and it’s clear why (NTRB) is on the radar right now. We have (NTRB) at the top of our screens right now. You might want to take a closer look at (NTRB) before the bell rings. Stay tuned—my next update is coming soon. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 02/13/2025 and ending on 02/14/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Headline Media LLC has been paid twenty-two thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither Media 1717 LLC, TD Media LLC and their member own shares of (NTRB:US). Please see important disclosure information here: https://marketcrux.com/disclosure/ntrb/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice